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ABSTRACT
Objectives To investigate the incidence of cancer in
arthritis patients treated with or without TNFα inhibitors
(TNF-I).
Methods Arthritis patients from the DANBIO database
were followed-up for cancer in the Danish Cancer
Registry during 2000–2008.
Results Hazard ratio for cancer overall was 1.02 (95%
confidence interval (CI) 0.80-1.30) in 3347 TNF-I-treated
RA patients compared to non-treated. Excess among
TNF-I-treated was found for colon cancer (HR 3.52 (95%
CI 1.11-11.15), whereas 6 and 0 ovarian cancer cases
were observed in treated and non-treated patients,
respectively. Compared to the general population, TNF-I-
treated RA patients had increased risk for cancer overall,
cancer in lymphatic-haematopoietic tissue and non-
melanoma skin cancer, while non-RA patients had no
increase in overall cancer risk.
Conclusions Our results suggest that TNF-I therapy in
routine care is not associated with an overall excess of
cancer in arthritis patients, but observed increased risks
of colon and ovarian cancer need further investigation.
INTRODUCTION
Treatment with TNFα inhibitors (TNF-I) is widely
used in inflammatory rheumatic diseases such as
rheumatoid arthritis (RA), ankylosing spondylitis
(AS) and psoriatic arthritis (PSA).
After more than 10 years of widespread use, it is
still debated whether treatment with TNF-I agents is
associated with an increase in cancer incidence,1–12
and additional observational studies with long-term
follow-up, detailed drug history and independent
registration of specific cancer cases are needed. The
aim of the present study was to investigate the risk
of cancer among TNF-I-treated patients by linking
the national Danish DANBIO database of arthritis
patients with the Danish Cancer Registry.
MATERIALS AND METHODS
DANBIO
Since 2000 Danish rheumatologists have voluntar-
ily registered patients treated with TNF-I agents
in the DANBIO database,13 and in 2006 reporting
became compulsory. Coverage for TNF-I-treated
patients is steadily greater than 90%. Since 2000,
an increasing number of both prevalent and newly
diagnosed non-TNF-I-treated arthritis patients
from rheumatology departments have also been
registered in DANBIO. At the beginning reporting
occurred on a voluntary basis but since 2006 the
departments have been committed to register all
newly diagnosed or newly referred RA patients. In
2006–7 a DANBIO-initiated cross-sectional study
involving 11 of 26 Danish outpatient departments
of rheumatology contributed with the registration
of 3704 RA patients in DANBIO, among these
2977 were TNF-I naive.14
For details of the Central Population Register,
the Danish Cancer Registry and statistical analysis,
see supplementary material (available online only).
Cohort identification and follow-up
A total of 10 495 patients registered in DANBIO
between January 2000 and December 2008 was
included. Among these patients, seven patients
with systemic lupus erythematosus and 52
patients with a missing diagnosis were excluded.
The remaining 10 436 patients were linked to the
Central Population Register (information on dates
of death or emigration) and to the Danish Cancer
Registry (identification of all cancer cases to 2008),
and 740 patients with a cancer diagnosis before
first registration in DANBIO were subsequently
excluded, leaving 9696 patients with arthritis for
analysis. Among these, 5345 started TNF-I therapy
between January 2000 and the end of 2008, while
4351 patients had never been treated with
anti-TNFα (table 1).
The cohort was followed from first registration
in DANBIO until the date of first cancer diagnosis,
death, emigration or the end of 2008, whichever
came first. For patients who did not start treat-
ment with TNF-I at the date of the first registra-
tion in DANBIO, the exposure status changed
from never exposed to ever exposed at the date of
the start of first TNF-I treatment (n=1475).
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RESULTS
The DANBIO arthritis cohort experienced 24,811 person-years
of observation, that is, 15,592 person-years accumulated after
TNF-I treatment and 9,219 person-years accumulated in non-
treated (never-treated patients and before TNF-I treatment).
The mean follow-up time was 2.9 years in TNF-I-treated
patients and 2.1 years in non-treated patients.
Overall, we observed 280 cancers in the total DANBIO RA
cohort, with 222.7 expected from the general population, yield-
ing a standardised incidence ratio (SIR) of 1.26 (95% CI 1.12 to
1.41). An increased SIR was observed for non-Hodgkin lymph-
oma 2.06 (95% CI 1.11 to 3.83), Hodgkin lymphoma 4.81 (95%
CI 1.20 to 19.2), non-melanoma skin cancer 1.84 (95% 1.47 to
2.31) and lung cancer 1.47 (95% CI 1.07 to 2.03). No increased
risk was observed for colon cancer 1.08 (95% CI 0.67 to 1.74).
No increase in the overall cancer risk was observed among
RA patients treated with TNF-I compared to non-treated
patients, whereas a significantly increased risk for all cancers
was observed when comparing TNF-I-treated RA patients with
the general population (table 2).
The same pattern with no increase in risk among TNF-I-treated
patients relative to non-treated patients, but an increase in risk
relative to the general population was seen for non-melanoma skin
cancer and cancer in lymphatic and haematopoietic tissue (table 2).
No increased risk of non-Hodgkin and Hodgkin lymphoma com-
bined was observed among RA patients receiving TNF-I therapy
when compared to patients not receiving therapy 0.92 (95% CI
0.29 to 2.92), while an increased SIR of 2.42 (95% CI 1.15 to 5.07)
was observed when compared to the general population.
A significantly increased risk of colon cancer (HR 3.52, 95% CI
1.11 to 11.15) was observed in TNF-I-treated RA patients com-
pared to non-treated patients, while a non-significantly increased
risk was seen compared to the general population (SIR 1.61, 95%
CI 0.93 to 2.77), based on 13 observed and 8.1 expected cases.
Among non-treated patients the SIR of colon cancer was 0.53
(95% CI 0.20 to 1.40). Six cases of ovarian cancer were seen in
TNF-I-treated RA patients, whereas no cases were observed in
non-treated patients. The risk of ovarian cancer was non-
significantly increased among those treated in comparison with
the general female population (SIR 2.08, 95% CI 0.94 to 4.64).
No significant increase in the risk for all cancer sites com-
bined was observed in any of the non-RA arthritis groups com-
pared to the general population.
Various adjustments for disease activity and stratified analyses
in TNF-I-treated RA patients compared to non-treated patients
did not reveal increased risks for overall cancer (table 3).
DISCUSSION
The strengths of our study include high coverage of biologically
treated patients (>90%) as well as a high validity of the RA,
AS and PSA diagnoses in the DANBIO Registry. The registra-
tion in DANBIO was independent of registration in the cancer
registry. We had complete follow-up and had the possibility to
compare the cancer risks in TNF-I-treated RA patients with
non-treated patients recruited from the same rheumatology
departments to minimise confounding, even though confound-
ing from factors influencing treatment decisions such as
comorbidity could not be avoided. Cancer incidence in both
treated and non-treated patients was also compared to that
of the general population of Denmark. In clinical practice in
Denmark, previous or actual cancer disease is generally a
contraindication for TNF-I treatment. Therefore, to avoid
differences in the prevalence of cancer among treated and non-
treated patients, we excluded all patients with a previous
cancer diagnosis. The cancer incidence during the first year
after initiating TNF-I treatment is most likely to be influenced
by selection bias, but exclusion of the first year after initiating
TNF-I treatment did not change the overall risk of cancer.
We found a moderately increased overall cancer risk in RA
compared to the general population. However, there was no
increase in overall cancer risk among RA patients treated with
TNF-I agents compared to RA non-treated patients, which is in
line with other observational studies,3 4 6 12 and a recent
meta-analysis.5 A meta-analysis of selected randomised trials of
RA patients in TNF-I treatment with adalimumab or infliximab
reported a three times increased risk of cancer during short-term
follow-up,1 which was not confirmed in a recent meta-analysis.2
Also in support of no effect of TNF-I on overall cancer incidence,
we found no evidence of an increase in overall risk by the cumu-
lative duration of anti-TNF therapy, and risks did not vary by
sex or age at the start of treatment.
In accordance with our findings, several studies have demon-
strated a two to fourfold increased risk of malignant lymphomas
in RA patients compared to the general population.7–9 12 15 The
incidence of lymphomas was the same in our TNF-I-treated and
non-treated RA patients, based on small numbers. Our results
Table 1 Number of arthritis patients in DANBIO and characteristics
of RA patients at first registration according to ever and never
treatment with TNF-I
Ever treated with
TNF-I*
Never-treated with
TNF-I
No of arthritis patients
All combined 5345 4351
RA 3347 3812
Ankylosing spondylitis 861 136
Psoriatic arthritis 656 224
Other arthritides 481 179
Characteristics of RA patients at start of follow-up
Mean age at start of follow-up,
years (range)
54.3 (15–87) 61.2 (15–92)
Mean age at diagnosis, years 44.9 51.8
No of men (%) 902 (27) 998 (26)
Calendar year of inclusion
2000–1 379 92
2002–3 561 46
2004–5 948 62
2006–7 1069 2807
2008 390 805
No of IgM RF seropositive† (%) 2411 (80) 2593 (74)
Mean disease duration, years
(range)
10.7 (0–59) 8.9 (0–68)
Proportion with disease duration
<2 years
18.7% 31.6%
Mean no of tender joints of
28 count† (range)
9.6 (0–28) 4.1 (0–28)
Mean no of swollen joints of
28 count† (range)
7.4 (0–28) 2.8 (0–28)
Mean HAQ score† (range) 1.3 (0–9.6) 0.7 (0–3.0)
Mean CRP, mg/l† (range) 27.0 (0–363) 15.2 (0–232)
Mean DAS28† (range) 5.1 (1.2–8.5) 3.5 (1.0–8.4)
*The number of rheumatoid arthriris (RA) patients ever treated with adalimumab
was 1529 (46%), etanercept 1488 (44%) and infliximab 1617 (48%).
†Patients with missing values were not included. The percentage of patients with
missing values was as follows (ever tumour necrosis factor α inhibitor (TNF-I)
treated, never-treated): number of IgM rheumatoid factor (RF) seropositive (9.7%,
8.4%), number of tender joints (7.3%, 3.5%), number of swollen joints (5.7%, 3.3%),
health assessment questionnaire (HAQ) score (18.1%, 16.6%), C-reactive protein
(CRP) (6.4%, 12.3%), disease activity score in 28 joints (DAS28) (20.4%, 29.4%).
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are in agreement with the conclusions of earlier
studies3 5 7 8 10 12 except a French study.9
We found an increased incidence of non-melanoma skin
cancer combining squamous and basal cell carcinomas in our
RA cohort compared to the general population, which is in
accordance with a previous Danish study of hospitalised
RA patients15 and studies of other immunosuppressive
cohorts.16 17 However, we found that the incidence of non-
melanoma skin cancer was similar for TNF-I-treated and non-
treated RA patients. A recently published British study reported
that skin cancer was increased among RA patients, but found
no evidence that TNF-I therapy exacerbated the risk of basal
cell or squamous cell carcinomas further.18
An increased risk of colon and ovarian cancer was observed in
RA patients treated with TNF-I agents compared to non-treated
patients. Evidence from previous studies concerning these
cancers is sparse. Wolfe and Michaud3 reported risks specifically
for colon and ovarian cancer when comparing TNF-I-treated
with untreated patients and the risks were not significantly ele-
vated. Surveillance bias does not seem an obvious explanation,
because increased surveillance would have been expected to
result in a general increase in cancer incidence at many
sites. One may hypothesise that a higher use of non-steroidal
anti-inflammatory drugs or aspirin in the disease-modifying
antirheumatic drug-treated group and a more sedentary lifestyle
in the TNF-I-treated group due to higher disability, as indicated
by the health assessment questionnaire or dietary factors,19 20
may affect the incidence rate of colon cancer. Larger studies are
needed to determine whether the increased risks of colon and
ovarian cancer were chance findings in our study.
In conclusion, we found no excess of overall cancer asso-
ciated with TNF-I therapy in RA patients in routine care.
However, increased risks of colon and ovary cancer were found
and need further investigation. We did not find an increase in
the overall cancer risk in TNF-I-treated AS, PSA and other
arthritides patients compared to the general population.
Table 2 Risk of cancer after treatment with TNF-I agents among patients with RA and patients with other types of arthritides
No of cancers
treated with TNF-I TNF-I treated vs
non-treated
TNF-I treated vs
general population
Non-treated vs
general population
Site* Yes No HR† (95% CI) SIR‡ (95% CI) SIR‡ (95% CI)
All cancer sites combined
RA patients 152 128 1.02 (0.80 to 1.30) 1.27 (1.08 to 1.49) 1.25 (1.05 to 1.48)
All non-RA 28 – 1.14 (0.79 to 1.65) –
AS 8 – 0.82 (0.41 to 1.64) –
PSA 12 – 1.16 (0.66 to 2.04) –
Other arthritides 8 – 1.80 (0.90 to 3.60) –
Specific sites for RA patients
Digestive organs 23 18 1.12 (0.60 to 2.11) 1.17 (0.78 to 1.76) 1.01 (0.64 to 1.60)
Colon 13 4 3.52 (1.11 to 11.15) 1.61 (0.93 to 2.77) 0.53 (0.20 to 1.40)
Rectum 2 6 0.28 (0.06 to 1.43) 0.45 (0.11 to 1.79) 1.53 (0.69 to 3.42)
Pancreas 3 3 0.72 (0.14 to 3.62) 1.09 (0.35 to 3.38) 1.23 (0.40 to 3.80)
Respiratory and intrathoracic organs 20 21 0.83 (0.45 to 1.55) 1.32 (0.85 to 2.05) 1.61 (1.05 to 2.47)
Lung 18 20 0.78 (0.41 to 1.49) 1.30 (0.82 to 2.07) 1.67 (1.08 to 2.59)
Skin 48 37 1.14 (0.73 to 1.78) 1.87 (1.41 to 2.48) 1.66 (1.20 to 2.29)
Melanoma of skin 6 3 1.54 (0.37 to 6.34) 1.57 (0.70 to 3.49) 1.00 (0.32 to 3.11)
Non-melanoma skin 42 34 1.10 (0.69 to 1.76) 1.92 (1.42 to 2.59) 1.76 (1.26 to 2.46)
Breast 14 14 0.73 (0.35 to 1.55) 0.69 (0.41 to 1.16) 0.89 (0.53 to 1.51)
Female genital organs 9 2 3.92 (0.84 to 18.41) 1.03 (0.53 to 1.97) 0.30 (0.07 to 1.19)
Corpus uteri 2 2 0.79 (0.11 to 5.58) 0.53 (0.13 to 2.13) 0.69 (0.17 to 2.75)
Ovary 6 0 – 2.08 (0.94 to 4.64) –
Male genital organs 6 10 0.64 (0.22 to 1.83) 0.89 (0.40 to 1.98) 1.42 (0.76 to 2.63)
Prostate 6 10 0.64 (0.22 to 1.83) 0.94 (0.42 to 2.09) 1.47 (0.79 to 2.72)
Urinary tract 9 7 1.12 (0.41 to 3.09) 1.31 (0.68 to 2.52) 1.12 (0.54 to 2.36)
Urinary bladder 5 5 0.77 (0.22 to 2.75) 1.09 (0.45 to 2.61) 1.16 (0.48 to 2.78)
Eye, brain, central nervous system 1 6 0.20 (0.02 to 1.73) 0.26 (0.04 to 1.85) 2.01 (0.90 to 4.47)
Lymphatic and haematopoietic tissue 14 9 1.25 (0.53 to 2.92) 2.24 (1.33 to 3.79) 1.66 (0.86 to 3.19)
Hodgkin lymphoma 2 0 – 8.27 (2.07 to 33.1) –
Non-Hodgkin lymphoma 5 5 0.63 (0.18 to 2.20) 1.88 (0.78 to 4.53) 2.27 (0.94 to 5.45)
Multiple myeloma 2 2 0.90 (0.13 to 6.44) 1.68 (0.42 to 6.74) 1.86 (0.47 to 7.45)
Lymphatic leukaemia 3 1 3.18 (0.33 to 31.08) 2.42 (0.78 to 7.49) 0.87 (0.12 to 6.19)
Ill-defined and unspecified cancer 4 2 1.51 (0.27 to 8.58) 1.31 (0.49 to 3.48) 0.68 (0.17 to 2.72)
*Only specific cancer sites with more than three cases in tumour necrosis factor α inhibitor (TNF-I)-treated and non-treated combined are shown. Results for Hodgkin lymphoma
are also presented.
†Estimated by HR ratios using Cox proportional hazard models with age as the underlying time scale and with further adjustment for sex and calendar time (2000–4, 2005–8).
HR was not calculated for anlylosing spondylitis (AS), psoriatric arthritis (PSA) or other arthritides patients because of the small number of patients and short follow-up time in
the non-TNF-I-treated group.
‡Estimated by standardised incidence ratios (SIR), ie, the ratio between observed and expected cancer cases during follow-up. The expected number of cancer cases was
calculated by multiplying the number of person-years experienced by the cohort members with sex and 5-year age and calendar-specific incidence rates for first cancers in the
general population in Denmark.
RA, rheumatoid arthritis.
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activity measures at the latest visit or at any time.
RA, rheumatoid arthritis.
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